Inventor · disambiguated record
Changyong Yang
Also filed as: YANG CHANGYONG
7 granted patents·11 pending applications·5 citations·filing 2017–2023
73Inventor score
Files withJIANGSU HENGRUI MEDICINE CO9SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD5BEIJING TUO JIE BIOPHARMACEUTICAL CO LTD1SHANGHAI SENHUI MEDICINE CO LTD1SHANGHAI SHENGDI PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
18 records- 0190US11208484B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Granted Dec 28, 2021·4 cites·9 claims
- 0289US11866500B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2021·Granted Jan 9, 2024·1 cites·17 claims
- 0382US12435144B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2023·Granted Oct 7, 2025·0 cites·19 claims
- 0455US2024217974A1Isoquinolone compound and use thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0553US12240904B2Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Mar 4, 2025·0 cites·16 claims
- 0650US2021196719A1Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseasesJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 0749US2024016822A1Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonistSHANGHAI SHENGDI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0849US2024382607A1Drug conjugate of eribulin derivativeSHANGHAI SENHUI MEDICINE CO LTD·Filed 2022·Application pending·0 cites
- 0947US2023220111A1Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereofBEIJING TUO JIE BIOPHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1047US2020054594A1Pharmaceutical composition containing mor agonist and kor agonist, and uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 1146US2022111008A1Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseasesJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 1245US11000518B2Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancerJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted May 11, 2021·0 cites·5 claims
- 1345US2023405138A1Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1445US2022017618A1Use of tim-3 antibody in preparation of medicines for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 1544US2020054764A1Medical use of anti-c met antibody-cytotoxic drug conjugateSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Application pending·0 cites
- 1643US11471503B2Use of KOR agonist in combination with MOR agonist in preparing drug for treating painJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Oct 18, 2022·0 cites·20 claims
- 1743US11065239B2Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumorJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jul 20, 2021·0 cites·20 claims
- 1834US2019224189A1Use of tyrosine-kinase inhibitor in preparing pharmaceutical product for cancer treatmentJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Changyong Yang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →